GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (NAS:DCTH) » Definitions » Equity-to-Asset

Delcath Systems (Delcath Systems) Equity-to-Asset

: 0.41 (As of Dec. 2023)
View and export this data going back to 2000. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Delcath Systems's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $15.78 Mil. Delcath Systems's Total Assets for the quarter that ended in Dec. 2023 was $38.61 Mil. Therefore, Delcath Systems's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.41.

The historical rank and industry rank for Delcath Systems's Equity-to-Asset or its related term are showing as below:

DCTH' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.18   Med: 0.22   Max: 0.76
Current: 0.41

During the past 13 years, the highest Equity to Asset Ratio of Delcath Systems was 0.76. The lowest was -2.18. And the median was 0.22.

DCTH's Equity-to-Asset is ranked worse than
76.69% of 871 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs DCTH: 0.41

Delcath Systems Equity-to-Asset Historical Data

The historical data trend for Delcath Systems's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.45 0.64 0.36 -0.33 0.41

Delcath Systems Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -0.43 -0.01 0.52 0.41

Competitive Comparison

For the Medical Devices subindustry, Delcath Systems's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Delcath Systems Equity-to-Asset Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Delcath Systems's Equity-to-Asset falls into.



Delcath Systems Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Delcath Systems's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=15.777/38.613
=0.41

Delcath Systems's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=15.777/38.613
=0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Delcath Systems  (NAS:DCTH) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Delcath Systems Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Delcath Systems's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Delcath Systems (Delcath Systems) Business Description

Traded in Other Exchanges
Address
1633 Broadway, Suite 22C, New York, NY, USA, 10019
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Executives
Vojo Vukovic officer: See Remarks C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Gerard J Michel director, officer: Chief Executive Officer 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Sandra Pennell officer: See Remarks C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
David L. Hoffman officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
John Purpura officer: EVP, Regulatory Affairs 600 FIFTH AVENUE, 23RD FLOOR, NEW YORK NY 10020
John Richard Sylvester director C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Salamon Steven A J director 25 ADMIRAL ROAD, TORONTO A6 M5R 2L4
Rosalind Advisors, Inc. director, other: See Remarks 15 WELLESLEY STREET WEST, SUITE 326, TORONTO A6 M4Y 0G7
Kevin Muir officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Anthony Dias officer: Vice President of Finance C/O SEACHANGE INTERNATIONAL, 50 NAGOG PARK, ACTON MA 01720
Gil Aharon director 15 WELLESLEY STREET WEST, SUITE 326, TORONTO A6 M4Y 0G7
Johnny John officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Elizabeth Czerepak director 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Christine Padula officer: See Remarks C/O DELCATH SYSTEMS, INC., 1633 BROADWAY, SUITE 22C, NEW YORK NY 10019
Simon Pedder director 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203

Delcath Systems (Delcath Systems) Headlines